A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder

References

• Sahai A , Khan MS , Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–2236.
   PubMed Web of Science ®Google Scholar
• Schmid DM , Sauermann P , Werner M , et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176(1):177–185.
   PubMed Web of Science ®Google Scholar
• Weil EH , Ruiz-Cerda JL , Eerdmans PH , et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol. 2000;37:161–171.
   PubMed Web of Science ®Google Scholar
• Wu JM , Siddiqui NY , Amundsen CL , et al. Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181(5):2181–2186.
   PubMed Web of Science ®Google Scholar
• Liberman JN , Hunt TL , Stewart WF , et al. Health related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology. 2001;57(6):1044–1050.
   PubMed Web of Science ®Google Scholar
• Abrams P , Kelleher CJ , Kerr LA , et al. Overactive bladder significantly affects quality of life. Am J Managed Care. 2000;6:S580–S590.
   PubMed Web of Science ®Google Scholar
• Al-Azzawi IS , Al-Tamimi MA. The first Iraqi experience in sacral neuromodulation for patients with lower urinary tract dysfunctions. Arab J Urol. 2018;16:391–396.
   PubMed Web of Science ®Google Scholar
• Colmann S , Chapple C , Nitti V , et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology. 2008;72:803–807.
   Web of Science ®Google Scholar
• Coyne KS , Sexton CC , Vats V , et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–1087.
   PubMed Web of Science ®Google Scholar
• Amundsen CL , Richter HE , Menefee SA , et al. Onabutulinum toxin A versus sacral neuromodulation on refractory urgency urinary incontinence in women. JAMA. 2016;316:1366–1374.
   PubMed Web of Science ®Google Scholar
• Chapple C , Sievert K-D , MacDiarmid S , et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–256.
   PubMed Web of Science ®Google Scholar
• Dunn J , Ellerkmann M , Bent A . Pathophysiology of detrusor overactivity. J Pelvic Med Surg. 2004;10:43–51.
   Google Scholar
• Rios LA , Averbeck MA , Franca W , et al. Initial experience with sacral neuromodulation for the treatment of lower urinary tract dysfunction in Brazil. Int Braz J Urol. 2014;42:312–320.
   Web of Science ®Google Scholar
• Weil EH , Ruiz-Cerda JL , Eerdmans PH , et al. Clinical results of sacral neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes. World J Urol. 1998;16:313–321.
   PubMed Web of Science ®Google Scholar
• Amundsen CL , Komesu YM , Chermansky C , et al. Two-year outcomes of SNM versus onabotulinum toxin A for refractory urgency urinary incontinence. A randomised Trial Eur Urol. 2018;74:66–73.
   PubMed Web of Science ®Google Scholar
• Sukhu T , Kennelly MJ , Kurpad R . Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol. 2016;8:193–199.
   PubMed Web of Science ®Google Scholar
• Hartmann KE , McPheeters ML , Biller DH , et al. Treatment of OAB in women. Evid Rep Technol Assess (Full Rep). 2009;187:94–95.
   Google Scholar
• Nobrega R , Greenwell TJ , Pickard R , et al. Sacral nerve stimulation versus intravesical botulinum toxin injections for medically refractory overactive bladder: a contemporary review of UK treatment from both clinician and patients’ perspectives. J Clin Urol. 2018;11:339–344.
   Web of Science ®Google Scholar
• Leong RK , de Wachter SG , Joore MA , et al. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A for patients with idiopathic overactive bladder. BJU Int. 2010;108:558–564.
   PubMed Web of Science ®Google Scholar
• Arlandis S , Castro D , Errando C , et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin A or continued medical management in refractory overactive bladder. Value Health. 2011;14:219–228.
   PubMed Web of Science ®Google Scholar